This information is intended for use by health professionalsEach film-coated tablet contains 400 mg moxifloxacin, corresponding to 436.37 mg moxifloxacin hydrochloride. Continue typing to refine. Concomitant administration of charcoal with a dose of 400 mg oral moxifloxacin will reduce systemic availability of the medicinal product by more than 80%. The study will also cover the cost of propranolol, up to $1,095, for 12 months.Leonberger Polyneuropathy / Laryngeal Paralysis & LeukoencephalomyelopathySample type for the detection of Mycoplasma hyopneumoniae with dimensions 19.4 x 7.8 mm in diameter and 5.8 mm in thicknessMoxifloxacin 400 mg film-coated tablets are indicated for the treatment of the following bacterial infections in patients of 18 years and older caused by bacteria susceptible to moxifloxacin (see sections 4.4, 4.8 and 5.1). Antibiotic-associated diarrhoea (AAD) and antibiotic-associated colitis (AAC), including pseudomembranous colitis and Moxifloxacin should be used with caution in patients with myasthenia gravis because the symptoms can be exacerbated. These effects were seen only after treatment with high doses of moxifloxacin or after prolonged treatment. Fluoroquinolones been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient; adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, … Moxifloxacin should be discontinued immediately at the first signs or symptoms of any serious adverse reaction and patients should be advised to contact their prescriber for advice.Moxifloxacin is not recommended for the treatment of MRSA infections. Animal studies have shown reproductive toxicity (see section 5.3). and monkeys (p.o.) Psychiatric reactions may occur even after the first administration of quinolones, including moxifloxacin. Due to adverse effects on the cartilage in juvenile animals (see section 5.3) the use of moxifloxacin in children and adolescents < 18 years is contraindicated (see section 4.3).This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.An additive effect on QT interval prolongation of moxifloxacin and other medicinal products that may prolong the QTc interval cannot be excluded. Patients under treatment with moxifloxacin should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop in order to prevent the development of potentially irreversible condition (see section 4.8). No studies on the effects of moxifloxacin on the ability to drive and use machines have been performed.
Patients should be advised to see how they react to moxifloxacin before driving or operating machinery.Adverse reactions observed in clinical trials and derived from post-marketing reports with moxifloxacin 400 mg (oral and sequential therapy) sorted by frequencies are listed below: Apart from nausea and diarrhoea all adverse reactions were observed at frequencies below 3%. The affected limb(s) should be appropriately treated (e.g. Patients with a family history of, or actual glucose-6-phosphate dehydrogenase deficiency are prone to haemolytic reactions when treated with quinolones. due to dizziness or vertigo)Seizures incl. Epidemiologic studies report an increased risk of aortic aneurysm and dissection after intake of fluoroquinolones, particularly in the older population. - Acute exacerbation of chronic obstructive pulmonary disease including bronchitis (adequately diagnosed)In acute exacerbation of chronic obstructive pulmonary disease including bronchitis Moxifloxacin should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections.